The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia

Louise Bordeleau, Natalia Yakubovich, Gilles R. Dagenais, Julio Rosenstock, Jeffrey Probstfield, Pan Chang Yu, Lars E. Ryden, Valdis Pirags, Giatgen A. Spinas, Kare I. Birkeland, Robert E. Ratner, Jose A. Marin-Neto, M. Keltai, Matthew C. Riddle, Jackie Bosch, Salim Yusuf, Hertzel C. Gerstein

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

OBJECTIVE: Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. We aimed to assess the effect of insulin glargine and n-3 fatty acids on incident cancers within the context of the ORIGIN (Outcome Reductionwith Initial Glargine Intervention) trial. RESEARCH DESIGN AND METHODS: The ORIGIN trial is an international, long-term, randomized two-by-two factorial study comparing insulin glargine with standard care and n-3 fatty acids with placebo (double blind) in people with dysglycemia at high risk for cardiovascular events. The primary outcome measure (cancer substudy) was the occurrence of any new or recurrent adjudicated cancer. Cancer mortality and cancer subtypes were also analyzed. RESULTS: Among 12,537 people (mean age 63.5 years, SD 7.8; 4,388 females), 953 developed a cancer event during the median follow-up of 6.2 years. In the glargine and standard care groups, the incidence of cancers was 1.32 and 1.32 per 100 person-years, respectively (P = 0.97), and in the n-3 fatty acid and placebo groups, it was 1.28 and 1.36 per 100 person-years, respectively (P = 0.39). No difference in the effect of either intervention was noted within predefined subgroups (P for all interactions ≥0.17). Cancer-related mortality and cancer-specific outcomes also did not differ between groups. Postrandomization HbA1c levels, glucose-lowering therapies (including metformin), and BMI did not affect cancer outcomes. CONCLUSIONS: Insulin glargine and n-3 fatty acids have a neutral association with overall and cancer-specific outcomes, including cancer-specific mortality. Exposure to glucose-lowering therapies, including metformin, and HbA1c level during the study did not alter cancer risk.

Original languageEnglish
Pages (from-to)1360-1366
Number of pages7
JournalDiabetes Care
Volume37
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Omega-3 Fatty Acids
Neoplasms
Metformin
Insulin Glargine
Glucose
Mortality
Placebos
Epidemiologic Studies

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Bordeleau, L., Yakubovich, N., Dagenais, G. R., Rosenstock, J., Probstfield, J., Yu, P. C., ... Gerstein, H. C. (2014). The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care, 37(5), 1360-1366. https://doi.org/10.2337/dc13-1468

The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. / Bordeleau, Louise; Yakubovich, Natalia; Dagenais, Gilles R.; Rosenstock, Julio; Probstfield, Jeffrey; Yu, Pan Chang; Ryden, Lars E.; Pirags, Valdis; Spinas, Giatgen A.; Birkeland, Kare I.; Ratner, Robert E.; Marin-Neto, Jose A.; Keltai, M.; Riddle, Matthew C.; Bosch, Jackie; Yusuf, Salim; Gerstein, Hertzel C.

In: Diabetes Care, Vol. 37, No. 5, 2014, p. 1360-1366.

Research output: Contribution to journalArticle

Bordeleau, L, Yakubovich, N, Dagenais, GR, Rosenstock, J, Probstfield, J, Yu, PC, Ryden, LE, Pirags, V, Spinas, GA, Birkeland, KI, Ratner, RE, Marin-Neto, JA, Keltai, M, Riddle, MC, Bosch, J, Yusuf, S & Gerstein, HC 2014, 'The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia', Diabetes Care, vol. 37, no. 5, pp. 1360-1366. https://doi.org/10.2337/dc13-1468
Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfield J, Yu PC et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care. 2014;37(5):1360-1366. https://doi.org/10.2337/dc13-1468
Bordeleau, Louise ; Yakubovich, Natalia ; Dagenais, Gilles R. ; Rosenstock, Julio ; Probstfield, Jeffrey ; Yu, Pan Chang ; Ryden, Lars E. ; Pirags, Valdis ; Spinas, Giatgen A. ; Birkeland, Kare I. ; Ratner, Robert E. ; Marin-Neto, Jose A. ; Keltai, M. ; Riddle, Matthew C. ; Bosch, Jackie ; Yusuf, Salim ; Gerstein, Hertzel C. / The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. In: Diabetes Care. 2014 ; Vol. 37, No. 5. pp. 1360-1366.
@article{71324680d8664a6cb13fada20a8b63d6,
title = "The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia",
abstract = "OBJECTIVE: Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. We aimed to assess the effect of insulin glargine and n-3 fatty acids on incident cancers within the context of the ORIGIN (Outcome Reductionwith Initial Glargine Intervention) trial. RESEARCH DESIGN AND METHODS: The ORIGIN trial is an international, long-term, randomized two-by-two factorial study comparing insulin glargine with standard care and n-3 fatty acids with placebo (double blind) in people with dysglycemia at high risk for cardiovascular events. The primary outcome measure (cancer substudy) was the occurrence of any new or recurrent adjudicated cancer. Cancer mortality and cancer subtypes were also analyzed. RESULTS: Among 12,537 people (mean age 63.5 years, SD 7.8; 4,388 females), 953 developed a cancer event during the median follow-up of 6.2 years. In the glargine and standard care groups, the incidence of cancers was 1.32 and 1.32 per 100 person-years, respectively (P = 0.97), and in the n-3 fatty acid and placebo groups, it was 1.28 and 1.36 per 100 person-years, respectively (P = 0.39). No difference in the effect of either intervention was noted within predefined subgroups (P for all interactions ≥0.17). Cancer-related mortality and cancer-specific outcomes also did not differ between groups. Postrandomization HbA1c levels, glucose-lowering therapies (including metformin), and BMI did not affect cancer outcomes. CONCLUSIONS: Insulin glargine and n-3 fatty acids have a neutral association with overall and cancer-specific outcomes, including cancer-specific mortality. Exposure to glucose-lowering therapies, including metformin, and HbA1c level during the study did not alter cancer risk.",
author = "Louise Bordeleau and Natalia Yakubovich and Dagenais, {Gilles R.} and Julio Rosenstock and Jeffrey Probstfield and Yu, {Pan Chang} and Ryden, {Lars E.} and Valdis Pirags and Spinas, {Giatgen A.} and Birkeland, {Kare I.} and Ratner, {Robert E.} and Marin-Neto, {Jose A.} and M. Keltai and Riddle, {Matthew C.} and Jackie Bosch and Salim Yusuf and Gerstein, {Hertzel C.}",
year = "2014",
doi = "10.2337/dc13-1468",
language = "English",
volume = "37",
pages = "1360--1366",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia

AU - Bordeleau, Louise

AU - Yakubovich, Natalia

AU - Dagenais, Gilles R.

AU - Rosenstock, Julio

AU - Probstfield, Jeffrey

AU - Yu, Pan Chang

AU - Ryden, Lars E.

AU - Pirags, Valdis

AU - Spinas, Giatgen A.

AU - Birkeland, Kare I.

AU - Ratner, Robert E.

AU - Marin-Neto, Jose A.

AU - Keltai, M.

AU - Riddle, Matthew C.

AU - Bosch, Jackie

AU - Yusuf, Salim

AU - Gerstein, Hertzel C.

PY - 2014

Y1 - 2014

N2 - OBJECTIVE: Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. We aimed to assess the effect of insulin glargine and n-3 fatty acids on incident cancers within the context of the ORIGIN (Outcome Reductionwith Initial Glargine Intervention) trial. RESEARCH DESIGN AND METHODS: The ORIGIN trial is an international, long-term, randomized two-by-two factorial study comparing insulin glargine with standard care and n-3 fatty acids with placebo (double blind) in people with dysglycemia at high risk for cardiovascular events. The primary outcome measure (cancer substudy) was the occurrence of any new or recurrent adjudicated cancer. Cancer mortality and cancer subtypes were also analyzed. RESULTS: Among 12,537 people (mean age 63.5 years, SD 7.8; 4,388 females), 953 developed a cancer event during the median follow-up of 6.2 years. In the glargine and standard care groups, the incidence of cancers was 1.32 and 1.32 per 100 person-years, respectively (P = 0.97), and in the n-3 fatty acid and placebo groups, it was 1.28 and 1.36 per 100 person-years, respectively (P = 0.39). No difference in the effect of either intervention was noted within predefined subgroups (P for all interactions ≥0.17). Cancer-related mortality and cancer-specific outcomes also did not differ between groups. Postrandomization HbA1c levels, glucose-lowering therapies (including metformin), and BMI did not affect cancer outcomes. CONCLUSIONS: Insulin glargine and n-3 fatty acids have a neutral association with overall and cancer-specific outcomes, including cancer-specific mortality. Exposure to glucose-lowering therapies, including metformin, and HbA1c level during the study did not alter cancer risk.

AB - OBJECTIVE: Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. We aimed to assess the effect of insulin glargine and n-3 fatty acids on incident cancers within the context of the ORIGIN (Outcome Reductionwith Initial Glargine Intervention) trial. RESEARCH DESIGN AND METHODS: The ORIGIN trial is an international, long-term, randomized two-by-two factorial study comparing insulin glargine with standard care and n-3 fatty acids with placebo (double blind) in people with dysglycemia at high risk for cardiovascular events. The primary outcome measure (cancer substudy) was the occurrence of any new or recurrent adjudicated cancer. Cancer mortality and cancer subtypes were also analyzed. RESULTS: Among 12,537 people (mean age 63.5 years, SD 7.8; 4,388 females), 953 developed a cancer event during the median follow-up of 6.2 years. In the glargine and standard care groups, the incidence of cancers was 1.32 and 1.32 per 100 person-years, respectively (P = 0.97), and in the n-3 fatty acid and placebo groups, it was 1.28 and 1.36 per 100 person-years, respectively (P = 0.39). No difference in the effect of either intervention was noted within predefined subgroups (P for all interactions ≥0.17). Cancer-related mortality and cancer-specific outcomes also did not differ between groups. Postrandomization HbA1c levels, glucose-lowering therapies (including metformin), and BMI did not affect cancer outcomes. CONCLUSIONS: Insulin glargine and n-3 fatty acids have a neutral association with overall and cancer-specific outcomes, including cancer-specific mortality. Exposure to glucose-lowering therapies, including metformin, and HbA1c level during the study did not alter cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=84899103659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899103659&partnerID=8YFLogxK

U2 - 10.2337/dc13-1468

DO - 10.2337/dc13-1468

M3 - Article

C2 - 24574355

AN - SCOPUS:84899103659

VL - 37

SP - 1360

EP - 1366

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -